Endocrine-Related Cancer

Papers
(The TQCC of Endocrine-Related Cancer is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Survival following resection of 10,244 lung neuroendocrine tumours: a population study111
Refining long-term surveillance requirements in patients with differentiated thyroid cancer67
Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study63
Acknowledgement to reviewers56
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas54
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing41
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications40
Update on the genetics of paragangliomas36
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression34
Targeting growth hormone in cancer: future perspectives34
Prognostic of recurrence and survival in poorly differentiated thyroid cancer32
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells31
Metastatic neuroendocrine neoplasms of the breast: a systematic review29
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs29
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms28
Radiation reprograms fibroblasts to drive prostate cancer therapy resistance27
NP-101 in combination with nivolumab and ipilimumab in metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A pilot study27
Defining aging-associated factors that increase susceptibility to prostate cancer24
The Diagnostic Value of 68Ga-Pentixafor PET/CT in Differentiating Adrenal Aldosterone-Producing Adenomas from Non-Functional Adenomas24
Impact of sex hormones on development and progression in NEN: a new therapeutic target?23
Metabolically active brown adipose tissue in PPGL: an observational cohort study22
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet21
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation21
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas21
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells20
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells20
Peptide receptor radionuclide therapy in malignant insulinoma20
Determinants of false-positive plasma free metanephrines and methoxytyramine: the role of medications and chronic disease20
PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs)17
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation17
Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid in Australia16
Gender-affirming care and endocrine-related cancers16
Defining the ATA-2025 ‘consider RAIT’ zone in older patients with N1b PTC16
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts16
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours15
Whole-exome sequencing of rectal neuroendocrine tumors15
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma15
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells14
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer14
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction14
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly14
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective13
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study13
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring13
Immunotherapy for endocrine tumours: a clinician’s perspective13
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen13
Elevated vasoactive intestinal peptide concentrations poorly predict VIPoma12
Ciliogenesis in pancreatic neuroendocrine tumors: insight into the role of WDR6012
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors12
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms12
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer12
Steroid profile in patients with breast cancer and in mice treated with mifepristone12
From bench to bedside in the sella: translational developments in pituitary tumour genetics12
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis12
Exploring stem cell biology in pituitary tumors and derived organoids12
ThyroidPrint®: clinical utility for indeterminate thyroid cytology12
Single-cell reveals age-dependent epithelial reprogramming and EMT vulnerability in THCA12
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma11
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review11
Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer11
Acknowledgement to reviewers11
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study11
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma11
Systems biology successes and areas for opportunity in prostate cancer11
Acknowledgement to reviewers11
Clinical features of plurihormonal pituitary adenoma subtypes11
In vivo and in vitro analysis of functional effects of the SDHD H50R variant11
Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR-(P)DTC10
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice10
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review10
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management10
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity10
Sexual dimorphism in thyroid cancer: evidence from preclinical studies10
Relationship between vascular density and microenvironment in medullary thyroid carcinoma10
Genetic disorders and insulinoma/glucagonoma10
Cancer in Ecuadorian subjects with Laron syndrome (ELS)10
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort10
Non-pituitary GH regulation of the tissue microenvironment10
ERRATUM: Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-210
NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors10
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland10
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma9
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid9
In memoriam: Charis Eng MD PhD (1962–2024)9
Beyond the three P’s: adrenal involvement in MEN19
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer9
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes9
Establishment of patient-derived xenografts for neuroendocrine tumors in the avian embryo model9
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal9
Genotype-specific development of MEN 2 constituent components in 683 RET carriers9
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L29
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer9
Deiodinases in thyroid tumorigenesis9
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms9
Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A9
Surrogate molecular classification of LAR breast cancer in routine workflow8
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer8
The science behind the relations among cancer, height, growth patterns, and growth hormone axis8
Genetic variants and down-regulation of CACNA1H in pheochromocytoma8
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover8
MicroRNAs as regulators of tumor metabolism8
Management of high-grade neuroendocrine neoplasms: impact of functional imaging8
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer8
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane8
0.081298112869263